Erick Lucera is the Chief Financial Officer at Dyne Therapeutics Inc., a clinical-stage biotechnology company pioneering precision genetic medicines to treat muscle diseases. With more than 20 years of experience in the biotech and pharmaceutical sectors, Lucera joined Dyne in February 2021 to lead its financial strategy during a critical phase of growth and clinical advancement. His leadership has been instrumental in securing substantial capital to fuel the company's innovative pipeline, including FORCE platform-enabled therapeutics targeting myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. Prior to Dyne, Lucera served as CFO at bluebird bio from 2019 to 2021, where he guided financial operations amid key clinical and regulatory milestones. Before that, he held progressively senior roles at Alkermes plc over 13 years, culminating as Senior Vice President of Finance and Treasurer, during which he orchestrated multiple debt and equity financings, mergers, and the company's transition to a public entity. Earlier in his career at Genzyme Corporation (now part of Sanofi), he built expertise in investor relations, treasury, and strategic planning. At Dyne, Lucera oversees all aspects of finance, including budgeting, forecasting, risk management, and investor relations, while supporting business development initiatives. His strategic acumen has enabled efficient resource allocation and positioned the company for long-term success in delivering transformative therapies. A Certified Public Accountant, Lucera holds a B.S. in Finance from Boston College.